T-cell engager

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Harbour BioMed and BMS collaboration on next-gen multi-specific antibodies

Lucid Diligence Brief: Harbour BioMed and BMS collaboration on next-gen…

by Timos Papagatsias

Hematology

Hematology Today—November 10, 2025

This week’s Hematology update spotlights  fresh breakthroughs, regulatory…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.